



**Alliance for Clinical Trials in Oncology**  
**Date** Friday, May 10, 2017  
**Loews Hotel Chicago O'Hare**  
**Time** 7:00 am – 10:00 pm

## Breast Committee Meeting Agenda

Chair(s): Lisa Carey and Ann Partridge  
 Vice-Chairs: Kelly Hunt (surgery) and Bruce Hafty (radiation)  
 Correlative Vice-Chairs: Ian Krop and Chuck Perou

<u>Time</u>	<u>Description</u>	<u>Presenters</u>
<b>7:00</b>	<b>Welcome and Introductions</b>	Carey & Partridge
	- Linda Ann Skoog-Sluman- ALLIANCE Executive Officer	
7:20	Correlative update	Krop & Perou
7:40	Liaison Reports:	
8:00	<b>New Concepts</b>	
	- Everolimus Dex concept (Symptom Intervention)	Rugo & Ruddy
	- HR+ MBC Optimal First-line Therapy- chemo "induction" or hormone-based therapy; de novo vs. recurrent dz	Traina (& King)
	- Late Relapse (LR) in HR+ HER2	Greenberg & Partridge
	- Brain Mets Biopsy Study	Brastianos & Anders
	<b>New Studies</b>	
	- AFT-030-BIG- Impassion (Adjuvant Atezolizumab)	McArthur
	- AFT-025- COMET (AS vs. GCC for DCIS)	Hwang
	- AFT-038-MBC-1- PATINA (endocrine therapy + anti-her2 therapy+/- palbo after THP, for triple pos dz)	Metzger
	<b>Ongoing Study Updates/Amendments/Issues</b>	
	- S1416- Phase II of cisplatin +/- veliparib in TNBC +brain	Anders
	- A011106- ALTERNATE	Ma
	- A011104- Preoperative breast MR	Bedrosian
	- A011202- AND post NAC	Boughey
	- A011203- Tam vs. Z-endoxifen in met disease	Goetz
	- A011401 (WtLoss-BWEL)	Ligibel
	- AFT05- PALLAS (Adjuvant palbo)	Mayer
	- A011502 (Aspirin)	Chen
	o Discuss co-enrollment of adjuvant trials strategies	
	- A221405- POSITIVE (endocrine interruption for preg-SI)	Partridge
	<b>Studies in Development</b>	
	- A221505 (hypo fx after mtx- SI Committee)	Poppe & Wagner
	- NCIC TailorRT (+/- XRT in low risk 1-3 Positive Nodes)	Ho & Bellon
	- Axillary reverse mapping (ARM) concept- SI Committee	Klimberg & Gallagher
	- AFT-? (ANG1005 in breast cancer lepto disease)	Kumthikar, Galanis Anders & Kaufman

10:00 Adjourn